Research published in the journal Lancet has confirmed that the Oxford-AstraZeneca vaccine is effective on average in 70 percent of cases
Oxford University and AstraZeneca on Tuesday released the final stage trial results of their corona vaccine update. Research published in the prestigious health-related journal Lancet has confirmed that the Oxford-AstraZeneca vaccine is effective on an average of 70 percent of cases. This report came during the positive developments on the vaccine. This is expected to help prevent the corona from the vaccine.
Market: Bulls’ passion high, record rally for 8th consecutive day in the market
Andrew Pollard, director of the Oxford Vaccine Group, said that publication in the Lancet showed that developers were sharing data transparently. He said that a series of vaccines would be needed to bring the corona epidemic to its heel, otherwise we would be in the same position in six months time. He points out that this cannot really be a competition between developers, it is to be in competition against the virus. Meanwhile Britain became the first country to begin vaccinations in Western countries on Tuesday, using a rival vaccine developed by Pfizer-BioNtech after being approved for general use last week.
Research suggests that two doses of the vaccine showed an efficiency of 62 percent, compared to 90 percent for those who were first given half and then a full dose. AstraZeneca and Oxford faced questions about their analysis last month, which looked at data from a total of 23,000 people in different trials with different protocols after releasing the results. These focused on the small group who were given the initial half dose due to a mistake.
PM Kisan Samman Nidhi Yojana: More than 2 crore farmers will get 4333 crore rupees in UP
Tuesday’s research confirmed that this group of 1,367 participants did not include adults older than 55 years. The authors stated that they provided additional analysis to Lancet peer reviewers, who suggested that better results for the half-dose group were not inferior to other factors of age. But he said more research would be needed. AstraZeneca said it would be up to regulators to decide, based on data, whether people would get the full dose after two full doses or half the dose.
Astrazeneca CEO Pascal Soriot said that I think it is fair to say that this needs to be looked at more to explain the intriguing result. They confirmed that the use of low initial doses was unplanned and the result of a measurement discrepancy, but once the researchers felt it was included in the trial, with the agreement of regulators. After the arrival of 32,080 new cases of Corona in the last 24 hours in India, the total number of cases has increased to 97,35,850. At the same time, after 402 new deaths, the total number of deaths reached 1,41,360. The number of active cases of corona virus is now 3,78,909. Whereas after 36,635 new discharges, the total number of discharges has increased to 92,15,581.
